- Published on
Emergency and Acute Medicine – Periodic Paralysis
Periodic paralysis is a disorder of skeletal muscle ion channel function that results in episodic flaccid weakness of the extremities. It is usually inherited and is triggered by abnormalities in serum potassium levels or thyrotoxicosis. Primary forms are familial and typically autosomal dominant mutations affecting skeletal muscle sodium, calcium, or potassium channels. Secondary forms include thyrotoxic, hypokalemic, and hyperkalemic variants.
Hypokalemic periodic paralysis is the most common form, with a prevalence of approximately 1 in 100,000, and about one-third of cases arise from new autosomal dominant mutations. Hyperkalemic periodic paralysis is less common, with a prevalence of 1 in 200,000, and most individuals with the mutation develop symptoms. Thyrotoxic periodic paralysis occurs in approximately 2% of patients with thyrotoxicosis, is more common in Asian populations, and is clinically similar to hypokalemic periodic paralysis. Andersen–Tawil syndrome is a rare subtype associated with periodic paralysis and cardiac arrhythmias.
The disorder results from mutations in skeletal muscle ion channel genes. Mutations in SCN4A affect sodium channels and are associated with both hypokalemic and hyperkalemic forms. Mutations in CACNA1S affect calcium channels and are linked to hypokalemic periodic paralysis. Andersen–Tawil syndrome is associated with mutations in the KCNJ2 gene. Age of onset varies: hypokalemic and Andersen–Tawil forms typically begin in the first or second decade, hyperkalemic in the first decade, and thyrotoxic periodic paralysis usually presents in the second to fifth decades.
Patients present with intermittent episodes of symmetrical muscle weakness, typically affecting the legs more than the arms. Attacks often have rapid onset and may recur, with some patients experiencing persistent mild weakness between episodes. Triggers include carbohydrate-rich meals, rest after strenuous exercise, illness, lack of sleep, medications such as insulin or β-agonists, cold exposure, menstruation, pregnancy, and thyroid dysfunction. Hypokalemic attacks may last from one hour to several days, hyperkalemic attacks usually last 15 minutes to 4 hours, and thyrotoxic attacks resemble hypokalemic episodes in duration.
On examination, patients are alert with intact sensation and normal sphincter tone. Weakness is symmetrical, reflexes are reduced or absent, and proximal muscles are often more affected. In thyrotoxic periodic paralysis, findings may include tachycardia, warm moist skin, goiter, or exophthalmos. Andersen–Tawil syndrome may present with dysmorphic features such as short stature, low-set ears, broad nasal base, and micrognathia, along with cardiac arrhythmias. Severe hypokalemia may rarely involve respiratory muscles.
Essential evaluation includes serum electrolytes and electrocardiography. In hypokalemic periodic paralysis, potassium is low or normal during attacks, and ECG may show sinus bradycardia, flattened T waves, or ST depression. In hyperkalemic periodic paralysis, potassium is normal or elevated and ECG may rarely show peaked T waves. In thyrotoxic periodic paralysis, potassium is decreased during attacks, and thyroid studies reveal suppressed TSH with elevated T4. ECG may show tachyarrhythmias, conduction abnormalities, or widened QRS complexes. Andersen–Tawil syndrome is associated with prolonged QT interval and ventricular arrhythmias. Imaging is not required in the emergency setting.
Management is primarily supportive with airway, breathing, and circulation stabilization, oxygen, IV access, and monitoring. In hypokalemic periodic paralysis, oral potassium replacement is preferred, typically 40 mEq, with cautious IV replacement if needed. Overcorrection must be avoided. In hyperkalemic periodic paralysis, many attacks resolve spontaneously, but IV calcium gluconate may help terminate an episode. In thyrotoxic periodic paralysis, treatment includes potassium replacement and management of thyrotoxicosis, often with a nonselective β-blocker for tachycardia. Andersen–Tawil syndrome requires careful potassium management and monitoring for arrhythmias. Patients with hypokalemic periodic paralysis should avoid volatile anesthetics and depolarizing neuromuscular blockers, as these may trigger attacks or malignant hyperthermia.
Admission is recommended for patients with severe electrolyte abnormalities, persistent weakness, cardiac arrhythmias, respiratory compromise, or Andersen–Tawil syndrome due to the risk of sudden cardiac death. Patients with resolved symptoms and no cardiopulmonary compromise may be discharged with referral to neurology, and endocrinology in cases of thyrotoxic periodic paralysis. Genetic counseling is appropriate in primary forms due to the 50% inheritance risk.
Early recognition and appropriate correction of electrolyte abnormalities are critical. Andersen–Tawil patients and those with persistent symptoms should be admitted. Caution with anesthetic agents is essential in all forms of periodic paralysis.
Periodic paralysis is a disorder of skeletal muscle ion channel function that results in episodic flaccid weakness of the extremities. It is usually inherited and is triggered by abnormalities in serum potassium levels or thyrotoxicosis. Primary forms are familial and typically autosomal dominant mutations affecting skeletal muscle sodium, calcium, or potassium channels. Secondary forms include thyrotoxic, hypokalemic, and hyperkalemic variants.
Hypokalemic periodic paralysis is the most common form, with a prevalence of approximately 1 in 100,000, and about one-third of cases arise from new autosomal dominant mutations. Hyperkalemic periodic paralysis is less common, with a prevalence of 1 in 200,000, and most individuals with the mutation develop symptoms. Thyrotoxic periodic paralysis occurs in approximately 2% of patients with thyrotoxicosis, is more common in Asian populations, and is clinically similar to hypokalemic periodic paralysis. Andersen–Tawil syndrome is a rare subtype associated with periodic paralysis and cardiac arrhythmias.
The disorder results from mutations in skeletal muscle ion channel genes. Mutations in SCN4A affect sodium channels and are associated with both hypokalemic and hyperkalemic forms. Mutations in CACNA1S affect calcium channels and are linked to hypokalemic periodic paralysis. Andersen–Tawil syndrome is associated with mutations in the KCNJ2 gene. Age of onset varies: hypokalemic and Andersen–Tawil forms typically begin in the first or second decade, hyperkalemic in the first decade, and thyrotoxic periodic paralysis usually presents in the second to fifth decades.
Patients present with intermittent episodes of symmetrical muscle weakness, typically affecting the legs more than the arms. Attacks often have rapid onset and may recur, with some patients experiencing persistent mild weakness between episodes. Triggers include carbohydrate-rich meals, rest after strenuous exercise, illness, lack of sleep, medications such as insulin or β-agonists, cold exposure, menstruation, pregnancy, and thyroid dysfunction. Hypokalemic attacks may last from one hour to several days, hyperkalemic attacks usually last 15 minutes to 4 hours, and thyrotoxic attacks resemble hypokalemic episodes in duration.
On examination, patients are alert with intact sensation and normal sphincter tone. Weakness is symmetrical, reflexes are reduced or absent, and proximal muscles are often more affected. In thyrotoxic periodic paralysis, findings may include tachycardia, warm moist skin, goiter, or exophthalmos. Andersen–Tawil syndrome may present with dysmorphic features such as short stature, low-set ears, broad nasal base, and micrognathia, along with cardiac arrhythmias. Severe hypokalemia may rarely involve respiratory muscles.
Essential evaluation includes serum electrolytes and electrocardiography. In hypokalemic periodic paralysis, potassium is low or normal during attacks, and ECG may show sinus bradycardia, flattened T waves, or ST depression. In hyperkalemic periodic paralysis, potassium is normal or elevated and ECG may rarely show peaked T waves. In thyrotoxic periodic paralysis, potassium is decreased during attacks, and thyroid studies reveal suppressed TSH with elevated T4. ECG may show tachyarrhythmias, conduction abnormalities, or widened QRS complexes. Andersen–Tawil syndrome is associated with prolonged QT interval and ventricular arrhythmias. Imaging is not required in the emergency setting.
Management is primarily supportive with airway, breathing, and circulation stabilization, oxygen, IV access, and monitoring. In hypokalemic periodic paralysis, oral potassium replacement is preferred, typically 40 mEq, with cautious IV replacement if needed. Overcorrection must be avoided. In hyperkalemic periodic paralysis, many attacks resolve spontaneously, but IV calcium gluconate may help terminate an episode. In thyrotoxic periodic paralysis, treatment includes potassium replacement and management of thyrotoxicosis, often with a nonselective β-blocker for tachycardia. Andersen–Tawil syndrome requires careful potassium management and monitoring for arrhythmias. Patients with hypokalemic periodic paralysis should avoid volatile anesthetics and depolarizing neuromuscular blockers, as these may trigger attacks or malignant hyperthermia.
Admission is recommended for patients with severe electrolyte abnormalities, persistent weakness, cardiac arrhythmias, respiratory compromise, or Andersen–Tawil syndrome due to the risk of sudden cardiac death. Patients with resolved symptoms and no cardiopulmonary compromise may be discharged with referral to neurology, and endocrinology in cases of thyrotoxic periodic paralysis. Genetic counseling is appropriate in primary forms due to the 50% inheritance risk.
Early recognition and appropriate correction of electrolyte abnormalities are critical. Andersen–Tawil patients and those with persistent symptoms should be admitted. Caution with anesthetic agents is essential in all forms of periodic paralysis.
0 Comments
